Physician profile
Gabriel Pai
NPI 1356388110
$8,984.43
in general payments reported to CMS, 2019-2025
34 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $607 · 2021: $1,342 · 2022: $1,710 · 2023: $1,521 · 2024: $1,487 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,558 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,557.84 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,680.63 | 2021-2025 | |
| Abbvie INC. | $1,487.13 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $802.89 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $628.75 | 2020-2025 | Nemluvio, Aklief, Epsolay |
| Pfizer INC. | $519.24 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $516.41 | 2020-2025 | Ilumya, Blu-U |
| Leo Pharma INC. | $482.20 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $442.39 | 2021-2025 | Opzelura |
| Almirall LLC | $395.96 | 2021-2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $372.30 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $225.19 | 2022-2024 | Vtama |
| Biofrontera INC. | $208.87 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Janssen Biotech, INC. | $193.88 | 2021-2025 | Tremfya, Stelara, Remicade |
| Lilly USA, LLC | $148.54 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Amgen INC. | $99.05 | 2019-2025 | Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $89.53 | 2019-2020 | |
| Genentech USA, INC. | $77.69 | 2021-2022 | |
| Celgene Corporation | $77.32 | 2019 | |
| Revance Therapeutics, INC. | $68.46 | 2024 | Daxxify |
| Allergan, INC. | $60.04 | 2022 | |
| Ucb, INC. | $46.29 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.83 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Epi Health, LLC | $38.84 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.03 | 2025 | |
| Mission Pharmacal Company | $32.03 | 2019 | |
| Bioventus LLC | $23.63 | 2022 | |
| Lifenet Health | $23.52 | 2024 | Theragenesis Wound Matrix |
| Organogenesis INC. | $23.45 | 2024 | Cygnus Dual |
| Misonix INC | $22.91 | 2021 | |
| Botanix Sb INC | $21.28 | 2025 | Sofdra |
| Taro Pharmaceuticals USA, INC. | $16.56 | 2019 | |
| Journey Medical Corporation | $14.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.